It is time to re-engage with 'true innovators' in pharma industry

US govt likely to be supportive of biomedical research

clock • 2 min read

The US Presidential Election has finally come and gone. It is time for investors to re-engage with the pharmaceutical and biotechnology sector.

For more than a year the sector has been under pressure as investors fret over the prospect of further healthcare system reform in the US, particularly government intervention in drug pricing in the wake of intense scrutiny on the practices of a handful of executives, who have exploited the structure of the notoriously complex US healthcare system.  While the fractious, obstructive nature of Washington politics is well known, we expect to see bipartisan efforts to close down opportunities for 'price gouging' behaviour on older generic medicines. How could a new president impact the US...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot